Inventiva S.A. (EPA:IVA)
France
· Delayed Price · Currency is EUR 3.160
-0.060 (-1.86%)
Apr 24, 2025, 5:35 PM CET
Inventiva Employees
As of December 31, 2024, Inventiva had 118 total employees, including 114 full-time and 4 part-time employees. The number of employees decreased by 5 or -4.07% compared to the previous year.
Employees
118
Change (1Y)
-5
Growth (1Y)
-4.07%
Revenue / Employee
€121,500
Profits / Employee
€1,588,034
Market Cap
302.29M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 153,498 |
| Sanofi | 82,878 |
| Sartorius Stedim Biotech | 9,901 |
| bioMérieux | 14,754 |
| Eurofins Scientific SE | 62,696 |
| Ipsen | 5,358 |
| Virbac | 5,620 |
| emeis Société anonyme | 83,000 |
Inventiva News
- 9 days ago - Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F - GlobeNewsWire
- 23 days ago - Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis - GlobeNewsWire
- 4 weeks ago - Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Inventiva reports its 2024 full year results and provides a business update - GlobeNewsWire
- 5 weeks ago - Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results - GlobeNewsWire
- 2 months ago - Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment - GlobeNewsWire
- 2 months ago - Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial - GlobeNewsWire
- 2 months ago - Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update - GlobeNewsWire